Cardio3 BioSciences , a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined.
http://ift.tt/1Dva5tV
http://ift.tt/1Dva5tV
No comments:
Post a Comment